Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)

NCT ID: NCT02313909

Last Updated: 2019-01-09

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE3

Total Enrollment

7213 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-12-23

Study Completion Date

2018-02-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a study in patients who recently had a brain attack (stroke) and in whom no clear cause of the stroke could be identified. These strokes are likely due to a blood clot and therefore, can be called embolic stroke of undetermined source. The abbreviation is ESUS. The study will compare 2 blood thinners. Patients will be randomly assigned to either Rivaroxaban 15 mg or Aspirin 100 mg and the study is intended to show, if patients given rivaroxaban have fewer blood clots in the brain (stroke) or in other blood vessels.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stroke

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Rivaroxaban

Rivaroxaban 15 mg orally once daily

Group Type EXPERIMENTAL

Rivaroxaban (Xarelto, BAY59-7939)

Intervention Type DRUG

15 mg, once daily, orally, tablet

Rivaroxaban-Placebo

Intervention Type OTHER

Matching placebo, once daily, orally, tablet

Aspirin

Aspirin 100 mg orally once daily

Group Type ACTIVE_COMPARATOR

Acetylsalicylic acid (Aspirin, BAY1019036)

Intervention Type DRUG

100 mg, once daily, orally, tablet

Aspirin-Placebo

Intervention Type OTHER

Matching placebo, once daily, orally, tablet

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Rivaroxaban (Xarelto, BAY59-7939)

15 mg, once daily, orally, tablet

Intervention Type DRUG

Acetylsalicylic acid (Aspirin, BAY1019036)

100 mg, once daily, orally, tablet

Intervention Type DRUG

Rivaroxaban-Placebo

Matching placebo, once daily, orally, tablet

Intervention Type OTHER

Aspirin-Placebo

Matching placebo, once daily, orally, tablet

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Recent ESUS (between 7 days and 6 months), defined as:
* Recent ischemic stroke (including transient ischemic attack with positive neuroimaging) visualized by brain imaging that is not lacunar, and
* Absence of cervical carotid atherosclerotic stenosis\> 50% or occlusion, and
* No atrial fibrillation after ≥ 24-hour cardiac rhythm monitoring, and
* No intra-cardiac thrombus on either transesophageal or transthoracic echocardiography, and
* No other specific cause of stroke (for example, arteritis, dissection, migraine/vasospasm, drug abuse)

Exclusion Criteria

* Severely disabling stroke (modified Rankin score ≥4)
* Indication for chronic anticoagulation or antiplatelet therapy
* Estimated glomerular filtration rate (eGFR) \< 30 mL/min/1.73 m\^2
Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Janssen Research & Development, LLC

INDUSTRY

Sponsor Role collaborator

Population Health Research Institute

OTHER

Sponsor Role collaborator

Bayer

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Bayer Study Director

Role: STUDY_DIRECTOR

Bayer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Tucson, Arizona, United States

Site Status

Long Beach, California, United States

Site Status

Stanford, California, United States

Site Status

Torrance, California, United States

Site Status

New Haven, Connecticut, United States

Site Status

Gainesville, Florida, United States

Site Status

Joliet, Illinois, United States

Site Status

Iowa City, Iowa, United States

Site Status

Lexington, Kentucky, United States

Site Status

New Orleans, Louisiana, United States

Site Status

Baltimore, Maryland, United States

Site Status

Boston, Massachusetts, United States

Site Status

Boston, Massachusetts, United States

Site Status

Worcester, Massachusetts, United States

Site Status

Ann Arbor, Michigan, United States

Site Status

Mount Clemens, Michigan, United States

Site Status

New Brunswick, New Jersey, United States

Site Status

Buffalo, New York, United States

Site Status

New York, New York, United States

Site Status

Cincinnati, Ohio, United States

Site Status

Cleveland, Ohio, United States

Site Status

Cleveland, Ohio, United States

Site Status

Portland, Oregon, United States

Site Status

Portland, Oregon, United States

Site Status

Erie, Pennsylvania, United States

Site Status

Philadelphia, Pennsylvania, United States

Site Status

Pittsburgh, Pennsylvania, United States

Site Status

Charleston, South Carolina, United States

Site Status

Columbia, South Carolina, United States

Site Status

Nashville, Tennessee, United States

Site Status

Austin, Texas, United States

Site Status

Dallas, Texas, United States

Site Status

El Paso, Texas, United States

Site Status

Houston, Texas, United States

Site Status

San Antonio, Texas, United States

Site Status

Temple, Texas, United States

Site Status

Salt Lake City, Utah, United States

Site Status

Seattle, Washington, United States

Site Status

Banfield, Buenos Aires, Argentina

Site Status

Ciudad Auton. de Buenos Aires, Buenos Aires, Argentina

Site Status

Mar del Plata, Buenos Aires, Argentina

Site Status

San Martín, Buenos Aires, Argentina

Site Status

Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina

Site Status

Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina

Site Status

Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina

Site Status

Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina

Site Status

Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina

Site Status

Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina

Site Status

Rosario, Santa Fe Province, Argentina

Site Status

Rosario, Santa Fe Province, Argentina

Site Status

Ciudad Auton. de Buenos Aires, , Argentina

Site Status

Córdoba, , Argentina

Site Status

Santa Fe, , Argentina

Site Status

Camperdown, New South Wales, Australia

Site Status

Waratah, New South Wales, Australia

Site Status

Brisbane, Queensland, Australia

Site Status

Southport, Queensland, Australia

Site Status

Launceston, Tasmania, Australia

Site Status

Clayton, Victoria, Australia

Site Status

Footscray, Victoria, Australia

Site Status

Murdoch, Western Australia, Australia

Site Status

Elizabeth Vale, , Australia

Site Status

Nedlands, , Australia

Site Status

Klagenfurt, Carinthia, Austria

Site Status

Villach, Carinthia, Austria

Site Status

Bad Pirawarth, Lower Austria, Austria

Site Status

Sankt Pölten, Lower Austria, Austria

Site Status

Feldbach, Styria, Austria

Site Status

Vöcklabruck, Upper Austria, Austria

Site Status

Feldkirch, Vorarlberg, Austria

Site Status

Salzburg, , Austria

Site Status

Vienna, , Austria

Site Status

Vienna, , Austria

Site Status

Bruges, West-Vlaanderen, Belgium

Site Status

Antwerp, , Belgium

Site Status

Brussels, , Belgium

Site Status

Bruxelles - Brussel, , Belgium

Site Status

Dendermonde, , Belgium

Site Status

Edegem, , Belgium

Site Status

Hasselt, , Belgium

Site Status

Salvador, Estado de Bahia, Brazil

Site Status

Belo Horizonte, Minas Gerais, Brazil

Site Status

Belo Horizonte, Minas Gerais, Brazil

Site Status

Porto Alegre, Rio Grande do Sul, Brazil

Site Status

Porto Alegre, Rio Grande do Sul, Brazil

Site Status

Porto Alegre, Rio Grande do Sul, Brazil

Site Status

Joinville, Santa Catarina, Brazil

Site Status

Botucatu, São Paulo, Brazil

Site Status

Campinas, São Paulo, Brazil

Site Status

Matão, São Paulo, Brazil

Site Status

Ribeirão Preto, São Paulo, Brazil

Site Status

Ribeirão Preto, São Paulo, Brazil

Site Status

São Paulo, São Paulo, Brazil

Site Status

São Paulo, São Paulo, Brazil

Site Status

Rio de Janeiro, , Brazil

Site Status

Calgary, Alberta, Canada

Site Status

Edmonton, Alberta, Canada

Site Status

Edmonton, Alberta, Canada

Site Status

Lethbridge, Alberta, Canada

Site Status

Vancouver, British Columbia, Canada

Site Status

Victoria, British Columbia, Canada

Site Status

Brandon, Manitoba, Canada

Site Status

Saint John, New Brunswick, Canada

Site Status

Halifax, Nova Scotia, Canada

Site Status

Burlington, Ontario, Canada

Site Status

Hamilton, Ontario, Canada

Site Status

Kingston, Ontario, Canada

Site Status

London, Ontario, Canada

Site Status

London, Ontario, Canada

Site Status

Mississauga, Ontario, Canada

Site Status

Ottawa, Ontario, Canada

Site Status

Thunder Bay, Ontario, Canada

Site Status

Toronto, Ontario, Canada

Site Status

Chicoutimi, Quebec, Canada

Site Status

Montreal, Quebec, Canada

Site Status

Montreal, Quebec, Canada

Site Status

Saint-Jérôme, Quebec, Canada

Site Status

Québec, , Canada

Site Status

Los Ángeles, Bío-Bío, Chile

Site Status

Osorno, Los Lagos Region, Chile

Site Status

Port Montt, Los Lagos Region, Chile

Site Status

Valdivia, Los Lagos Region, Chile

Site Status

Viña del Mar, Región de Valparaíso, Chile

Site Status

Santiago, , Chile

Site Status

Santiago, , Chile

Site Status

Viña del Mar, , Chile

Site Status

Fuzhou, Fujian, China

Site Status

Fuzhou, Fujian, China

Site Status

Lanzhou, Gansu, China

Site Status

Foshan, Guangdong, China

Site Status

Guangzhou, Guangdong, China

Site Status

Haikou, Hainan, China

Site Status

Shijiazhuang, Hebei, China

Site Status

Harbin, Heilongjiang, China

Site Status

Zhengzhou, Henan, China

Site Status

Wuhan, Hubei, China

Site Status

Wuhan, Hubei, China

Site Status

Wuhan, Hubei, China

Site Status

Changsha, Hunan, China

Site Status

Baotou, Inner Mongolia, China

Site Status

Nantong, Jiangsu, China

Site Status

Nanchang, Jiangxi, China

Site Status

Changchun, Jilin, China

Site Status

Shenyang, Liaoning, China

Site Status

Qingdao, Shandong, China

Site Status

Yantai, Shandong, China

Site Status

Baoji, Shanxi, China

Site Status

Xi’an, Shanxi, China

Site Status

Kunming, Yunnan, China

Site Status

Hangzhou, Zhejiang, China

Site Status

Taizhou, Zhejiang, China

Site Status

Wenzhou, Zhejiang, China

Site Status

Beijing, , China

Site Status

Beijing, , China

Site Status

Chongqing, , China

Site Status

Guangzhou, , China

Site Status

Shanghai, , China

Site Status

Tianjin, , China

Site Status

Tianjin, , China

Site Status

Blansko, , Czechia

Site Status

Brno, , Czechia

Site Status

Brno, , Czechia

Site Status

Hradec Králové, , Czechia

Site Status

Jihlava, , Czechia

Site Status

Olomouc, , Czechia

Site Status

Ostrava Vitkovice, , Czechia

Site Status

Ostrava-Poruba, , Czechia

Site Status

Prague, , Czechia

Site Status

Prague, , Czechia

Site Status

Vyškov, , Czechia

Site Status

Aalborg, , Denmark

Site Status

Aarhus C, , Denmark

Site Status

Copenhagen, , Denmark

Site Status

Glostrup Municipality, , Denmark

Site Status

Herlev, , Denmark

Site Status

Hillerød, , Denmark

Site Status

Helsinki, , Finland

Site Status

Lappeenranta, , Finland

Site Status

OYS, , Finland

Site Status

Sairaalamäki, , Finland

Site Status

Tampere, , Finland

Site Status

Turku, , Finland

Site Status

Vaasa, , Finland

Site Status

Antony, , France

Site Status

Bordeaux, , France

Site Status

Brest, , France

Site Status

Caen, , France

Site Status

Dijon, , France

Site Status

Le Chesnay, , France

Site Status

Limoges, , France

Site Status

Nantes, , France

Site Status

Nîmes, , France

Site Status

Paris, , France

Site Status

Paris, , France

Site Status

Paris, , France

Site Status

Paris, , France

Site Status

Paris, , France

Site Status

Saint-Priest-en-Jarez, , France

Site Status

Strasbourg, , France

Site Status

Freiburg im Breisgau, Baden-Wurttemberg, Germany

Site Status

Mannheim, Baden-Wurttemberg, Germany

Site Status

München, Bavaria, Germany

Site Status

Regensburg, Bavaria, Germany

Site Status

Würzburg, Bavaria, Germany

Site Status

Hanover, Lower Saxony, Germany

Site Status

Düsseldorf, North Rhine-Westphalia, Germany

Site Status

Meerbusch, North Rhine-Westphalia, Germany

Site Status

Wuppertal, North Rhine-Westphalia, Germany

Site Status

Dresden, Saxony, Germany

Site Status

Dresden, Saxony, Germany

Site Status

Markkleeberg, Saxony, Germany

Site Status

Wermsdorf, Saxony, Germany

Site Status

Halle, Saxony-Anhalt, Germany

Site Status

Altenburg, Thuringia, Germany

Site Status

Berlin, , Germany

Site Status

Hamburg, , Germany

Site Status

Athens, , Greece

Site Status

Athens, , Greece

Site Status

Ioannina, , Greece

Site Status

Larissa, , Greece

Site Status

Thessaloniki, , Greece

Site Status

Budapest, , Hungary

Site Status

Budapest, , Hungary

Site Status

Budapest, , Hungary

Site Status

Debrecen, , Hungary

Site Status

Eger, , Hungary

Site Status

Győr, , Hungary

Site Status

Kistarcsa, , Hungary

Site Status

Miskolc, , Hungary

Site Status

Nagykanizsa, , Hungary

Site Status

Nyíregyháza, , Hungary

Site Status

Sopron, , Hungary

Site Status

Szeged, , Hungary

Site Status

Zalaegerszeg, , Hungary

Site Status

Dublin, , Ireland

Site Status

Galway, , Ireland

Site Status

Ashkelon, , Israel

Site Status

Beersheba, , Israel

Site Status

Haifa, , Israel

Site Status

Haifa, , Israel

Site Status

Jerusalem, , Israel

Site Status

Petah Tikva, , Israel

Site Status

Ramat Gan, , Israel

Site Status

Tel Aviv, , Israel

Site Status

L’Aquila, Abruzzo, Italy

Site Status

Vibo Valentia, Calabria, Italy

Site Status

Parma, Emilia-Romagna, Italy

Site Status

Trieste, Friuli Venezia Giulia, Italy

Site Status

Rome, Lazio, Italy

Site Status

Rome, Lazio, Italy

Site Status

Rome, Lazio, Italy

Site Status

Rome, Lazio, Italy

Site Status

Milan, Lombardy, Italy

Site Status

Milan, Lombardy, Italy

Site Status

Milan, Lombardy, Italy

Site Status

Pavia, Lombardy, Italy

Site Status

Isernia, Molise, Italy

Site Status

Cagliari, Sardinia, Italy

Site Status

Ancona, The Marches, Italy

Site Status

Perugia, Umbria, Italy

Site Status

Perugia, Umbria, Italy

Site Status

Perugia, Umbria, Italy

Site Status

Verona, Veneto, Italy

Site Status

Verona, Veneto, Italy

Site Status

Nagoya, Aichi-ken, Japan

Site Status

Nagoya, Aichi-ken, Japan

Site Status

Nagoya, Aichi-ken, Japan

Site Status

Okazaki, Aichi-ken, Japan

Site Status

Seto, Aichi-ken, Japan

Site Status

Toyota, Aichi-ken, Japan

Site Status

Kitakyushu, Fukuoka, Japan

Site Status

Kitakyushu, Fukuoka, Japan

Site Status

Kōriyama, Fukushima, Japan

Site Status

Fukuyama, Hiroshima, Japan

Site Status

Asahikawa, Hokkaido, Japan

Site Status

Hakodate, Hokkaido, Japan

Site Status

Kushiro, Hokkaido, Japan

Site Status

Kobe, Hyōgo, Japan

Site Status

Kobe, Hyōgo, Japan

Site Status

Kobe, Hyōgo, Japan

Site Status

Nishinomiya, Hyōgo, Japan

Site Status

Isehara, Kanagawa, Japan

Site Status

Kawasaki, Kanagawa, Japan

Site Status

Sendai, Miyagi, Japan

Site Status

Sasebo, Nagasaki, Japan

Site Status

Tenri, Nara, Japan

Site Status

Kurashiki, Okayama-ken, Japan

Site Status

Matsubara, Osaka, Japan

Site Status

Sakai, Osaka, Japan

Site Status

Suita, Osaka, Japan

Site Status

Hidaka, Saitama, Japan

Site Status

Bunkyo-ku, Tokyo, Japan

Site Status

Hachiōji, Tokyo, Japan

Site Status

Kodaira, Tokyo, Japan

Site Status

Musashino, Tokyo, Japan

Site Status

Shinjuku-ku, Tokyo, Japan

Site Status

Sumida-ku, Tokyo, Japan

Site Status

Fukuoka, , Japan

Site Status

Fukuoka, , Japan

Site Status

Fukuoka, , Japan

Site Status

Hiroshima, , Japan

Site Status

Kakogawa, , Japan

Site Status

Kochi, , Japan

Site Status

Kyoto, , Japan

Site Status

Kyoto, , Japan

Site Status

Kyoto, , Japan

Site Status

Niigata, , Japan

Site Status

Okayama, , Japan

Site Status

Gustavo Adolfo Madero, Mexico City, Mexico

Site Status

México, D.F., Mexico City, Mexico

Site Status

Morelia, Michoacán, Mexico

Site Status

México D.F., México, Mexico

Site Status

Monterrey, Nuevo León, Mexico

Site Status

Mérida, Yucatán, Mexico

Site Status

Aguascalientes, , Mexico

Site Status

México D.F., , Mexico

Site Status

Bialystok, , Poland

Site Status

Chełm, , Poland

Site Status

Gdansk, , Poland

Site Status

Gdansk, , Poland

Site Status

Gmina Końskie, , Poland

Site Status

Katowice, , Poland

Site Status

Lodz, , Poland

Site Status

Lodz, , Poland

Site Status

Olsztyn, , Poland

Site Status

Sandomierz, , Poland

Site Status

Siedlce, , Poland

Site Status

Skarżysko-Kamienna, , Poland

Site Status

Warsaw, , Poland

Site Status

Warsaw, , Poland

Site Status

Warsaw, , Poland

Site Status

Vilanova de Gaia, Porto District, Portugal

Site Status

Almada, , Portugal

Site Status

Amadora, , Portugal

Site Status

Coimbra, , Portugal

Site Status

Lisbon, , Portugal

Site Status

Porto, , Portugal

Site Status

Porto, , Portugal

Site Status

Vila Franca de Xira, , Portugal

Site Status

Chelyabinsk, , Russia

Site Status

Kaluga, , Russia

Site Status

Kazan', , Russia

Site Status

Krasnoyarsk, , Russia

Site Status

Moscow, , Russia

Site Status

Moscow, , Russia

Site Status

Nizhny Novgorod, , Russia

Site Status

Saint Petersburg, , Russia

Site Status

Saint Petersburg, , Russia

Site Status

Saint Petersburg, , Russia

Site Status

Saint Petersburg, , Russia

Site Status

Tomsk, , Russia

Site Status

Ulyanovsk, , Russia

Site Status

Volgograd, , Russia

Site Status

Yaroslavl, , Russia

Site Status

Yekaterinburg, , Russia

Site Status

Yekaterinburg, , Russia

Site Status

Cape Town, Western Cape, South Africa

Site Status

Somerset West, Western Cape, South Africa

Site Status

Durban, , South Africa

Site Status

Donggu, Gwangju Gwang''yeogsi, South Korea

Site Status

Anyang-si, Gyeonggido, South Korea

Site Status

Goyang, Gyeonggido, South Korea

Site Status

Seongnam-si, Gyeonggido, South Korea

Site Status

Seoul, Seoul Teugbyeolsi, South Korea

Site Status

Busan, , South Korea

Site Status

Daegu, , South Korea

Site Status

Daegu, , South Korea

Site Status

Incheon, , South Korea

Site Status

Seoul, , South Korea

Site Status

Seoul, , South Korea

Site Status

Seoul, , South Korea

Site Status

Seoul, , South Korea

Site Status

Seoul, , South Korea

Site Status

Seoul, , South Korea

Site Status

Santiago de Compostela, A Coruña, Spain

Site Status

Badalona, Barcelona, Spain

Site Status

L'Hospitalet de Llobregat, Barcelona, Spain

Site Status

Sant Joan Despí, Barcelona, Spain

Site Status

Castellon, Castellón, Spain

Site Status

El Palmar (Murcia), Murcia, Spain

Site Status

A Coruña, , Spain

Site Status

Badajoz, , Spain

Site Status

Barcelona, , Spain

Site Status

Barcelona, , Spain

Site Status

Barcelona, , Spain

Site Status

Barcelona, , Spain

Site Status

Bilbao, , Spain

Site Status

Cáceres, , Spain

Site Status

Girona, , Spain

Site Status

Granada, , Spain

Site Status

León, , Spain

Site Status

Lleida, , Spain

Site Status

Madrid, , Spain

Site Status

Madrid, , Spain

Site Status

Madrid, , Spain

Site Status

Seville, , Spain

Site Status

Seville, , Spain

Site Status

Valencia, , Spain

Site Status

Valladolid, , Spain

Site Status

Zaragoza, , Spain

Site Status

Gothenburg, , Sweden

Site Status

Hässleholm, , Sweden

Site Status

Lund, , Sweden

Site Status

Malmo, , Sweden

Site Status

Umeå, , Sweden

Site Status

Aarau, Canton of Aargau, Switzerland

Site Status

Basel, Canton of Basel-City, Switzerland

Site Status

Lugano, Canton Ticino, Switzerland

Site Status

Baden, , Switzerland

Site Status

Bern, , Switzerland

Site Status

Fribourg, , Switzerland

Site Status

Geneva, , Switzerland

Site Status

Zurich, , Switzerland

Site Status

Ankara, , Turkey (Türkiye)

Site Status

Ankara, , Turkey (Türkiye)

Site Status

Antakya, , Turkey (Türkiye)

Site Status

Istanbul, , Turkey (Türkiye)

Site Status

Istanbul, , Turkey (Türkiye)

Site Status

Kahramanmaraş, , Turkey (Türkiye)

Site Status

Konya, , Turkey (Türkiye)

Site Status

Konya, , Turkey (Türkiye)

Site Status

High Wycombe, Buckinghamshire, United Kingdom

Site Status

Milton Keynes, Buckinghamshire, United Kingdom

Site Status

Cambridge, Cambridgeshire, United Kingdom

Site Status

Exeter, Devon, United Kingdom

Site Status

Colchester, Essex, United Kingdom

Site Status

Westcliff-on-Sea, Essex, United Kingdom

Site Status

Gloucester, Gloucestershire, United Kingdom

Site Status

Watford, Hertfordshire, United Kingdom

Site Status

Ashford, Kent, United Kingdom

Site Status

Margate, Kent, United Kingdom

Site Status

Leicester, Leicestershire, United Kingdom

Site Status

Boston, Lincolnshire, United Kingdom

Site Status

Harrow, London, United Kingdom

Site Status

Great Yarmouth, Norfolk, United Kingdom

Site Status

Taunton, Somerset, United Kingdom

Site Status

Yeovil, Somerset, United Kingdom

Site Status

Sheffield, South Yorkshire, United Kingdom

Site Status

Stoke-on-Trent, Staffordshire, United Kingdom

Site Status

Glasgow, Stratchclyde, United Kingdom

Site Status

Gateshead, Tyne and Wear, United Kingdom

Site Status

Sunderland, Tyne and Wear, United Kingdom

Site Status

Wolverhampton, West Midlands, United Kingdom

Site Status

Leeds, West Yorkshire, United Kingdom

Site Status

Salisbury, Wiltshire, United Kingdom

Site Status

Aberdeen, , United Kingdom

Site Status

Durham, , United Kingdom

Site Status

Edinburgh, , United Kingdom

Site Status

London, , United Kingdom

Site Status

London, , United Kingdom

Site Status

London, , United Kingdom

Site Status

London, , United Kingdom

Site Status

Luton, , United Kingdom

Site Status

Norwich, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Argentina Australia Austria Belgium Brazil Canada Chile China Czechia Denmark Finland France Germany Greece Hungary Ireland Israel Italy Japan Mexico Poland Portugal Russia South Africa South Korea Spain Sweden Switzerland Turkey (Türkiye) United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Hart RG, Sharma M, Mundl H, Kasner SE, Bangdiwala SI, Berkowitz SD, Swaminathan B, Lavados P, Wang Y, Wang Y, Davalos A, Shamalov N, Mikulik R, Cunha L, Lindgren A, Arauz A, Lang W, Czlonkowska A, Eckstein J, Gagliardi RJ, Amarenco P, Ameriso SF, Tatlisumak T, Veltkamp R, Hankey GJ, Toni D, Bereczki D, Uchiyama S, Ntaios G, Yoon BW, Brouns R, Endres M, Muir KW, Bornstein N, Ozturk S, O'Donnell MJ, De Vries Basson MM, Pare G, Pater C, Kirsch B, Sheridan P, Peters G, Weitz JI, Peacock WF, Shoamanesh A, Benavente OR, Joyner C, Themeles E, Connolly SJ; NAVIGATE ESUS Investigators. Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source. N Engl J Med. 2018 Jun 7;378(23):2191-2201. doi: 10.1056/NEJMoa1802686. Epub 2018 May 16.

Reference Type RESULT
PMID: 29766772 (View on PubMed)

Kasner SE, Lavados P, Sharma M, Wang Y, Wang Y, Davalos A, Shamalov N, Cunha L, Lindgren A, Mikulik R, Arauz A, Lang W, Czlonkowska A, Eckstein J, Gagliardi R, Amarenco P, Ameriso SF, Tatlisumak T, Veltkamp R, Hankey GJ, Toni DS, Bereczki D, Uchiyama S, Ntaios G, Yoon BW, Brouns R, DeVries Basson MM, Endres M, Muir K, Bornstein N, Ozturk S, O'Donnell M, Mundl H, Pater C, Weitz J, Peacock WF, Swaminathan B, Kirsch B, Berkowitz SD, Peters G, Pare G, Themeles E, Shoamanesh A, Connolly SJ, Hart RG; NAVIGATE ESUS Steering Committee and Investigators. Characterization of Patients with Embolic Strokes of Undetermined Source in the NAVIGATE ESUS Randomized Trial. J Stroke Cerebrovasc Dis. 2018 Jun;27(6):1673-1682. doi: 10.1016/j.jstrokecerebrovasdis.2018.01.027. Epub 2018 Mar 7.

Reference Type RESULT
PMID: 29525076 (View on PubMed)

Hart RG, Sharma M, Mundl H, Shoamanesh A, Kasner SE, Berkowitz SD, Pare G, Kirsch B, Pogue J, Pater C, Peters G, Davalos A, Lang W, Wang Y, Wang Y, Cunha L, Eckstein J, Tatlisumak T, Shamalov N, Mikulik R, Lavados P, Hankey GJ, Czlonkowska A, Toni D, Ameriso SF, Gagliardi RJ, Amarenco P, Bereczki D, Uchiyama S, Lindgren A, Endres M, Brouns R, Yoon BW, Ntaios G, Veltkamp R, Muir KW, Ozturk S, Arauz A, Bornstein N, Bryer A, O'Donnell MJ, Weitz J, Peacock F, Themeles E, Connolly SJ. Rivaroxaban for secondary stroke prevention in patients with embolic strokes of undetermined source: Design of the NAVIGATE ESUS randomized trial. Eur Stroke J. 2016 Sep;1(3):146-154. doi: 10.1177/2396987316663049. Epub 2016 Aug 3.

Reference Type RESULT
PMID: 31008276 (View on PubMed)

Lee SF, Whiteley W, Bosch J, Sherlock L, Cukierman-Yaffe T, O'Donnell M, Eikelboom JW, Gerstein HC, Bangdiwala SI, Muniz-Terrera G. Improving analysis of cognitive outcomes in cardiovascular trials using different statistical approaches. Trials. 2024 Oct 2;25(1):644. doi: 10.1186/s13063-024-08482-2.

Reference Type DERIVED
PMID: 39358761 (View on PubMed)

Sharma M, Smith EE, Pearce LA, Perera KS, Kasner SE, Yoon BW, Ameriso SF, Puig J, Damgaard D, Fiebach JB, Muir KW, Veltkamp RC, Toni DS, Shamalov N, Gagliardi RJ, Mikulik R, Engelter ST, Bereczki D, O'Donnell MJ, Saad F, Shoamanesh A, Berkowitz SD, Mundl H, Hart RG; NAVIGATE ESUS MRI Substudy Investigators. Rivaroxaban versus aspirin for prevention of covert brain infarcts in patients with embolic stroke of undetermined source: NAVIGATE ESUS MRI substudy. Int J Stroke. 2022 Aug;17(7):799-805. doi: 10.1177/17474930211058012. Epub 2021 Nov 18.

Reference Type DERIVED
PMID: 34791941 (View on PubMed)

Merkler AE, Pearce LA, Kasner SE, Shoamanesh A, Birnbaum LA, Kamel H, Sheth KN, Sharma R. Left Ventricular Dysfunction Among Patients With Embolic Stroke of Undetermined Source and the Effect of Rivaroxaban vs Aspirin: A Subgroup Analysis of the NAVIGATE ESUS Randomized Clinical Trial. JAMA Neurol. 2021 Dec 1;78(12):1454-1460. doi: 10.1001/jamaneurol.2021.3828.

Reference Type DERIVED
PMID: 34694346 (View on PubMed)

Sharma M, Smith EE, Pearce LA, Shoamanesh A, Perera KS, Coutts SB, Damgaard D, Ameriso SF, Rha JH, Modrau B, Yoon BW, Romano M, Messe SR, Barlinn J, Lambeck J, Saad F, Berkowitz SD, Mundl H, Connolly SJ, Hart RG; NAVIGATE ESUS MIND MRI Substudy Investigators. Frequency and Patterns of Brain Infarction in Patients With Embolic Stroke of Undetermined Source: NAVIGATE ESUS Trial. Stroke. 2022 Jan;53(1):45-52. doi: 10.1161/STROKEAHA.120.032976. Epub 2021 Sep 20.

Reference Type DERIVED
PMID: 34538089 (View on PubMed)

Shoamanesh A, Hart RG, Connolly SJ, Kasner SE, Smith EE, Marti-Fabregas J, Liu YY, Uchiyama S, Mikulik R, Veltkamp R, O'Donnell MJ, Ntaios G, Muir KW, Field TS, Santo GC, Olavarria V, Mundl H, Lutsep H, Berkowitz SD, Sharma M. Microbleeds and the Effect of Anticoagulation in Patients With Embolic Stroke of Undetermined Source: An Exploratory Analysis of the NAVIGATE ESUS Randomized Clinical Trial. JAMA Neurol. 2021 Jan 1;78(1):11-20. doi: 10.1001/jamaneurol.2020.3836.

Reference Type DERIVED
PMID: 33074284 (View on PubMed)

Scheitz JF, Pare G, Pearce LA, Mundl H, Peacock WF, Czlonkowska A, Sharma M, Nolte CH, Shoamanesh A, Berkowitz SD, Krahn T, Endres M; NAVIGATE-ESUS Biomarker Working Group. High-Sensitivity Cardiac Troponin T for Risk Stratification in Patients With Embolic Stroke of Undetermined Source. Stroke. 2020 Aug;51(8):2386-2394. doi: 10.1161/STROKEAHA.120.029628. Epub 2020 Jul 9.

Reference Type DERIVED
PMID: 32640945 (View on PubMed)

Veltkamp R, Pearce LA, Korompoki E, Sharma M, Kasner SE, Toni D, Ameriso SF, Mundl H, Tatlisumak T, Hankey GJ, Lindgren A, Berkowitz SD, Arauz A, Ozturk S, Muir KW, Chamorro A, Perera K, Shuaib A, Rudilosso S, Shoamanesh A, Connolly SJ, Hart RG. Characteristics of Recurrent Ischemic Stroke After Embolic Stroke of Undetermined Source: Secondary Analysis of a Randomized Clinical Trial. JAMA Neurol. 2020 Oct 1;77(10):1233-1240. doi: 10.1001/jamaneurol.2020.1995.

Reference Type DERIVED
PMID: 32628266 (View on PubMed)

Mikulik R, Eckstein J, Pearce LA, Mundl H, Rudilosso S, Olavarria VV, Shoamanesh A, Chamorro A, Marti-Fabregas J, Veltkamp R, Ozturk S, Tatlisumak T, Peacock WF, Berkowitz SD, Connolly SJ, Hart RG. Frequency and Predictors of Major Bleeding in Patients With Embolic Strokes of Undetermined Source: NAVIGATE-ESUS Trial. Stroke. 2020 Jul;51(7):2139-2147. doi: 10.1161/STROKEAHA.119.027995. Epub 2020 Jun 10.

Reference Type DERIVED
PMID: 32517582 (View on PubMed)

Ntaios G, Pearce LA, Veltkamp R, Sharma M, Kasner SE, Korompoki E, Milionis H, Mundl H, Berkowitz SD, Connolly SJ, Hart RG; NAVIGATE ESUS Investigators. Potential Embolic Sources and Outcomes in Embolic Stroke of Undetermined Source in the NAVIGATE-ESUS Trial. Stroke. 2020 Jun;51(6):1797-1804. doi: 10.1161/STROKEAHA.119.028669. Epub 2020 Apr 16.

Reference Type DERIVED
PMID: 32295509 (View on PubMed)

Martinez-Majander N, Ntaios G, Liu YY, Ylikotila P, Joensuu H, Saarinen J, Perera KS, Marti-Fabregas J, Chamorro A, Rudilosso S, Prats-Sanchez L, Berkowitz SD, Mundl H, Themeles E, Tiainen M, Demchuk A, Kasner SE, Hart RG, Tatlisumak T; NAVIGATE ESUS investigators. Rivaroxaban versus aspirin for secondary prevention of ischaemic stroke in patients with cancer: a subgroup analysis of the NAVIGATE ESUS randomized trial. Eur J Neurol. 2020 May;27(5):841-848. doi: 10.1111/ene.14172. Epub 2020 Mar 11.

Reference Type DERIVED
PMID: 32056346 (View on PubMed)

Ntaios G, Pearce LA, Meseguer E, Endres M, Amarenco P, Ozturk S, Lang W, Bornstein NM, Molina CA, Pagola J, Mundl H, Berkowitz SD, Liu YY, Sen S, Connolly SJ, Hart RG. Aortic Arch Atherosclerosis in Patients With Embolic Stroke of Undetermined Source: An Exploratory Analysis of the NAVIGATE ESUS Trial. Stroke. 2019 Nov;50(11):3184-3190. doi: 10.1161/STROKEAHA.119.025813. Epub 2019 Sep 17.

Reference Type DERIVED
PMID: 31526123 (View on PubMed)

Ntaios G, Swaminathan B, Berkowitz SD, Gagliardi RJ, Lang W, Siegler JE, Lavados P, Mundl H, Bornstein N, Meseguer E, Amarenco P, Cucchiara B, Camps-Renom P, Makaritsis K, Korompoki E, Papavasileiou V, Marti-Fabregas J, Milionis H, Vemmos K, Connolly SJ, Hart RG; NAVIGATE ESUS Investigators. Efficacy and Safety of Rivaroxaban Versus Aspirin in Embolic Stroke of Undetermined Source and Carotid Atherosclerosis. Stroke. 2019 Sep;50(9):2477-2485. doi: 10.1161/STROKEAHA.119.025168. Epub 2019 Aug 12.

Reference Type DERIVED
PMID: 31401971 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Statistical Analysis Plan

View Document

Document Type: Study Protocol

View Document

Related Links

Access external resources that provide additional context or updates about the study.

https://clinicaltrials.bayer.com/

Click here to find results for studies related to Bayer products.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2013-000768-27

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

16573

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Edoxaban for TIA and Acute Minor Stroke
NCT02221102 UNKNOWN PHASE2/PHASE3